
-
Valneva SE NASDAQ:VALN Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden and Vienna, Austria, with other offices in France, Canada and the United States.
Location: Campus Bio-Ouest, 6, Rue Alain Bombard, Pays De La Loire, 44800, France | Website: https://valneva.com/ | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.19B
Cash
168.3M
Avg Qtr Burn
-16.8M
Short % of Float
0.01%
Insider Ownership
0.00%
Institutional Own.
0.87%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IXCHIQ (VLA1553) Details Chikungunya, Infectious disease | Approved Quarterly sales | |
IXCHIQ (VLA1553) Details Chikungunya, Viral infection | Phase 3 Update | |
IXCHIQ (VLA1553) Details Chikungunya, Viral infection | Phase 3 Initiation | |
IXCHIQ (VLA1553) Details Chikungunya, Viral infection | Phase 3 Initiation | |
Shigella4V2 (S4V2) Details Shigella, Nasolabial fold lines | Phase 2 Data readout | |
VLA15 Details Lyme disease, Bacterial infection | Phase 2 Data readout | |
VLA1601 Details Viral infection, Zika virus | Phase 1 Data readout | |
VLA2001 Details Infectious disease, COVID-19 | Failed Discontinued |